Finally, among the myriad of emerging immunotherapy agents for cancer, an antibody that achieves T cell activation by blocking a negative regulatory pathway has an obvious dose and schedule pharmacological advantages over pure agonists. We have, however, entered the era of combinations. Optimal immune...
(R/M HNSCC). The AK117-302 study represents a significant milestone as the first Phase III clinical trial globally to investigate a CD47 monoclonal antibody therapy for solid tumors. This trial is the fifth Phase III study for ivonescimab, utilizing PD-1/L1 monoclonal antibody therapy as a ...
626.Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical TrialsAnti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)...
In this study, we further developed and assessed a novel fully human anti-CD47 antibody, AMMS4-G4, derived from ZF1 using affinity maturation. AMMS4-G4 exhibited equivalent anticancer effects with Hu5F9-G4, a humanized anti-CD47 antibody in clinical trial, on the potential of inducing ...
Second, rats had an intracaudate co-injection of 50 μL autologous blood with either CD47 blocking antibody or IgG. MRI was used to quantify hematoma/iron volume, hemolysis, brain swelling, and atrophy at different time points, behavioral tests to assess neurological deficits, and ...
The CD47 antibody is commonly used in clinical trials for lymphomas, and its anti-tumor activity depends on the IgG subtype, which binds FcγR to active Fc-mediated functions. The fully human antibody has lower immunogenicity and higher safety than humanized antibody, but side effects such as ...
Antibody humanization is important for reducing the immunogenic responses associated with animal-derived antibodies. Numerous antibodies are commercialized as therapeutics, however, the immunogenicity of animal-derived antibodies may restrict their application in clinical. According to previous research [52], ...
clinical trials [107,108,109,110]. Targeting CD47 to disrupt its interaction with SIRPα can enhance the immune system’s ability to destroy cancer cells and could be explored to prevent autoinflammatory diseases. Anti–neutrophil cytoplasmic antibody (ANCA)–associated vasculitis is an ...
Toggle Sidebar Find Previous Next of 0 Presentation ModeOpenPrintDownloadCurrent View Tools Zoom Out Zoom In Automatic ZoomActual SizePage FitPage Width50%75%100%125%150%200%300%400%
AO-176, a highly differentiated clinical stage Anti-CD47 antibody, exerts Potent Anti-tumor Activity in Preclinical models of multiple myeloma as a single Agent and in combination with approved therapeutics. Blood. 2020;136:3–4. Article Google Scholar Golubovskaya V, Berahovich R, Zhou H, ...